Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
VALENCIA, Calif., Feb. 16, 2016 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, announced today that it will present at the RBC Capital Markets 2016 Healthcare Conference on Tuesday, February 23, 2016 at 10:00 AM (ET) at The Palace Hotel, in New York, NY.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Matthew J. Pfeffer Chief Executive Officer (661) 775-5300 [email protected]
